regorafenib + toripalimab + celecoxib

The drug combination **regorafenib + toripalimab + celecoxib** represents a therapeutic regimen combining three distinct medications with complementary mechanisms of action, likely employed as a multi-modal approach to cancer treatment. **Toripalimab** is a humanized monoclonal antibody that targets PD-1 (programmed death-1), a checkpoint protein on T-cells. It works by blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2), preventing the "off" signal that would normally inhibit T-cell activity[3][5][7]. This blockade allows T-cells to remain active and continue targeting cancer cells[5]. Toripalimab has shown significant clinical benefits, particularly in patients with PD-L1 expressing tumors[2]. It has a 12-fold higher binding affinity to PD-1 than pembrolizumab and promotes significantly more Th1- and myeloid-derived inflammatory cytokine responses[2]. The binding of toripalimab to PD-1 is mainly attributed to the heavy chain of toripalimab and the FG loop of PD-1[4]. This component contributes immunotherapy to the combination. **Celecoxib** is a selective noncompetitive inhibitor of cyclooxygenase-2 (COX-2) enzyme[6]. Unlike most NSAIDs that inhibit both COX-1 and COX-2, celecoxib specifically targets COX-2, which is expressed heavily in inflamed tissues[6]. This selective inhibition reduces the synthesis of inflammatory mediators like prostaglandin E2, prostacyclin, thromboxane, and others, leading to pain and inflammation relief[6]. Celecoxib is primarily used to treat pain and inflammation caused by conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and menstrual pain[8][10]. It's also used in juvenile rheumatoid arthritis in children over 2 years old[8]. Additionally, celecoxib has demonstrated anticancer effects by binding to the cadherin-11 protein and inhibiting the PDK-1 signaling mechanism, as well as inhibiting carbonic anhydrase enzymes 2 and 3[6]. Celecoxib provides anti-inflammatory properties with potential anticancer effects. **Regorafenib** is included as a targeted therapy component in this combination. (Specific mechanism details for regorafenib were not provided in the search results.) This combination may offer synergistic benefits in treating certain types of cancer, though specific clinical data on this exact combination is not provided in the search results.